Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | Biomarker | phenotype | BEFREE | The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. | 25907102 | 2016 | ||||
|
0.070 | GeneticVariation | phenotype | BEFREE | In conclusion, MRD monitoring early after transplant allows further rapid identification of t(8;21) patients at high risk of relapse and was more predictive of relapse risk than c-KIT mutations. | 25082877 | 2014 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | To improve MRD assessment by MFC, we here evaluate the combination of human Myeloid Inhibitory C-type Lectin (hMICL, also termed C-type lectin domain family 12, member A, CLEC12A) and CD 123 (also termed interleukin-3 receptor alpha, IL3RA) in combination with CD34 and CD117 (KIT), as an MRD assay in pre-clinical and clinical testing in 69 AML patients. | 24152218 | 2014 | ||||
|
0.070 | GeneticVariation | phenotype | BEFREE | Modern risk factors include KIT and/or FLT3 gene mutations and minimal residual disease (MRD) levels, but their respective values have never been prospectively assessed. | 23321257 | 2013 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. | 19603346 | 2009 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Our results indicate that quantitative analysis of CD34 and CD117 may be useful to detect minimal residual disease (MRD) and could be tested in a future to monitor therapy in AML. | 12008077 | 2002 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | It has been suggested that CD117 in combination with other antigens may be of great help for the identification of leukemia-associated phenotypes that could be used to monitor MRD in both acute myeloid leukemias and multiple myeloma patients achieving morphological complete remission. | 9711908 | 1998 |